Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

780.67 +1.39 (+0.18%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
2 Stocks to Buy on the Dip and Hold for 10 Years
Via The Motley Fool
2 Dividend Growth Stocks to Buy and Hold Forever
Via The Motley Fool
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies . 
Via Benzinga
Topics Government
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Via The Motley Fool
Topics Artificial Intelligence
The 9 Best Stocks to Buy Now in July (2025)
Via The Motley Fool
Topics Artificial Intelligence
1 Unstoppable Vanguard Growth ETF to Buy With $400 in July
Via The Motley Fool
Topics Artificial Intelligence ETFs
2 Cash-Producing Stocks Worth Investigating and 1 to Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Can Buying the Vanguard S&P 500 ETF Make You a Millionaire?
Via The Motley Fool
Topics ETFs Economy Stocks
2 Growth Stocks to Buy Hand Over Fist in July
These companies are poised to produce fireworks for your portfolio over the coming years. 
Via The Motley Fool
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
Via The Motley Fool
The health-care stocks to watch as treatment innovations shake up patient care
Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of health-care companies to 
Via Equities.com
Topics Economy
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound. 
Via Benzinga
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Via The Motley Fool
Is the Vanguard S&P 500 Index Fund ETF a Buy Now?
Via The Motley Fool
Topics ETFs Economy Government
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
$1,000 Invested in VUG Could Turn Into $50,000
Via The Motley Fool
Topics ETFs Economy
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value 
Via MarketBeat
Topics Artificial Intelligence Economy
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)
Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
Which Stock Will Dominate the Weight Management Market Through 2030?
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs
MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations. 
Via Benzinga
GLP-1 Showdown In India: Eli Lilly’s Mounjaro Pen Approved Just Days After Novo’s Wegovy Launch
Local drugmakers, including Sun Pharma, Biocon, Zydus, Cipla, and Dr. Reddy’s are racing to develop cheaper versions of semaglutide as its Indian patent nears expiry. 
Via Stocktwits
Topics Intellectual Property
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
Why This Weight Loss Drug Company's Stock Surged Today
Via The Motley Fool
3 Growth Stocks I'm Loading Up On
Via The Motley Fool
Topics Artificial Intelligence Government
5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings Call
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the... 
Via StockStory
Topics Earnings World Trade
Why Shares in Novo Nordisk Lost Weight Today
Via The Motley Fool
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years. 
Via Benzinga
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss. 
Via Investor's Business Daily
What's Going On With Viking Therapeutics Stock On Wednesday?
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.